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ABSTRACT 
Oxytocin is a hormone which plays a crucial role in many reproductive and behavioural 
functions. It affects many organs and the classical peripheral targets are the mammary glands 
during lactation and uterus during labour. Oxytocin receptors have recently been described in 
a variety of normal tissues and primary cell cultures, but also in neoplastic tissues and 
established neoplastic cell lines, as breast cancer cell lines. The signalling pathways and 
biological effects of the oxytocin/oxytocin receptor system seem to depend on species, type of 
tissue, physiological versus neoplastic state and receptor location within the cell membrane. 
The aim of this project was to find out if the cell proliferation in the canine mammary 
carcinoma cell line CMT-U27 was affected upon stimulation of oxytocin, and to investigate 
the presence of oxytocin receptors in these cells. The cell proliferation was examined by using 
an ELISA-kit, where the absorbance measured is relative to the amount of living cells. 
Immunocytochemistry was used to detect possible oxytocin receptors. 
The results showed that there was significant inhibition of the cell proliferation with the 
addition of oxytocin. In three different assays at least one cell concentration showed 
significant inhibition of the cell growth. The immunocytochemistry analysis showed the 
presence of oxytocin receptors and based on the location of the receptors it seemed to be at 
least two groups within the cell line. Some of the cells show marked staining in the nuclear 
membrane and some seemed to be unstained or had weak staining in the cell membrane or 
cytoplasm. 
Since the location of the oxytocin receptors show that they have been activated, further 
studies can find out which of the cells that produce oxytocin, and if the possible synthesis 
leads to paracrine or autocrine stimulation. 
Keywords: canine mammary carcinoma cells, oxytocin, oxytocin receptors  
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SAMMANFATTNING 
Oxytocin är ett hormon som spelar en viktig roll i många funktioner för reproduktion och 
beteende. Det påverkar många organ och vävnader, de klassiska perifera målorganen är 
mjölkkörtlarna vid laktation och livmodern under förlossning. Oxytocinreceptorer har nyligen 
beskrivits i en mängd normala vävnader och primära cellkulturer, men även i neoplastisk 
vävnad och etablerade neoplastiska cellinjer, som cellinjer från bröstcancertumörer. 
Signalvägarna och de biologiska effekterna av oxytocin/oxytocinreceptor-systemet verkar 
bero på art, vävnadstyp, fysiologisk kontra neoplastisk status och receptorns plats i 
cellmembranet. 
Syftet med det här projektet var att ta reda på om celltillväxten i cellinjen CMT-U27 från 
juvercarcinom hos hund påverkades av oxytocinstimulering samt att undersöka förekomsten 
av oxytocinreceptorer i dessa celler. Celltillväxten analyserades med hjälp av ett ELISA-kit, 
där den uppmätta absorbansen är relativ mot antalet levande celler. Immunocytokemi 
användes för att undersöka förekomsten av oxytocinreceptorer. 
Resultaten visade på signifikant inhibering av celltillväxten vid tillsats av oxytocin. I tre olika 
analysomgångar visade minst en cellkoncentration på signifikant inhibering av celltillväxten. 
Immunocytokemianalysen påvisade förekomst av oxytocinreceptorer och baserat på 
receptorernas placering verkade det finnas minst två grupper inom cellinjen. Några celler var 
starkt infärgade i kärnmembranet och några verkade helt ofärgade eller hade svagare 
infärgning i cellmembranet eller cytoplasman. 
Eftersom oxytocinreceptorernas position visar att de blivit aktiverade kan ytterligare studier ta 
reda på vilka celler som producerar oxytocin, samt om det leder till parakin eller autokrin 
stimulering. 
Nyckelord: juvercarcinomceller hos hund, oxytocin, oxytocinreceptorer 
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INTRODUCTION 
Mammary tumours in dogs are the second most common group of neoplasms, following skin 
tumours (McCarthy et al., 2003). In areas where early ovariectomy of bitches is not routinely 
done, the incidence is high. For intact dogs, middle-aged bitches (nine to eleven years) are 
primarily affected, and an increase in incidence begins at approximately six years of age 
(Alenza et al., 2000). In the case of breast cancer in human there is a correlation between the 
age of a woman’s first child and the chance of developing breast cancer. Earlier childbirth 
gives a lower chance of developing breast cancer. It is thought that the first full-term 
pregnancy changes the state of differentiation of the cells in the breast, which alters their 
subsequent hormonal responses (Alberts et al., 2002). 
Oxytocin receptors (OTRs) have been detected in several human cancer tissues and cell lines, 
including human breast cancer. OTRs were found in over 80% of the breast cancers, but no 
apparent relationship between OTR expression and other clinical variables was found (Zingg 
& Laporte, 2003). Cassoni et al. (2006) has detected OTRs in contractile myoepithelial cells, 
in primary breast carcinomas and in breast carcinoma cell lines. Oxytocin (OT) regulates cell 
proliferation in breast carcinoma cells via OTRs. The study shows local synthesis of OT 
within the human mammary gland under both normal and neoplastic conditions. Normal 
myoepithelial cells were able to synthesize and secrete OT and different carcinoma cell lines 
were able to synthesize and release OT. Both normal epithelial and myoepithelial cells 
contain mRNA for OT, but only myoepithelial cells actively produce and release OT in the 
culture medium. This suggests the possibility of a local autocrine loop involving 
myoepithelial cells, but has not yet been confirmed. In the referred study normal mammary 
epithelial cells did not show active synthesis and release of OT in the culture medium. 
OT can have an inhibitory effect on cell growth. In studies of human breast cancer it has been 
found that OT also can inhibit breast cancer cell proliferation by down-regulating the 
mitogenic effects mediated by estrogens (Reversi et al., 2006). 
The aim of this project was to find out if the cell proliferation in the canine mammary 
carcinoma CMT-U27 cells was affected upon stimulation with OT, and to investigate the 
presence of OTRs in these cells. 
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BACKGROUND 
The mammary gland is developed during life, particularly during puberty, pregnancy, and 
after parturition, and is not fully matured until the female has given birth to an offspring. 
During the foetal development the mammary gland develops the main large ducts and a 
nipple. In humans, the growth is isometric before puberty. With the onset of puberty (8-12 
years) allometric growth of the stroma and epithelium begins. During puberty, increasing 
elongation and branching of the ducts creates a more extensive ductal network. The bud-like 
structures at the end of the ducts, which is the major site of growth, form the terminal duct 
lobular units. During the first half of the pregnancy intensified lobular–alveolar growth 
together with extension and branching of the ductal system occurs. The mammary gland 
growth is influenced by a number of hormones, e.g. oestrogen, progesterone, prolactin and 
growth hormone. By mid-pregnancy, there is some secretory development and in the last 
trimester, there is a further increase in lobular size (Geddes, 2007). 
An essential role for OT is milk ejection from the mammary gland. It is critical for successful 
lactation, because only small volumes of milk can be removed from the lactating breast before 
milk ejection (Geddes, 2007). The release of milk is triggered by stimulation of the nipple, 
which generates sensory impulses that are transmitted via nervous impulses to the secretory 
oxytocinergic neurons in the hypothalamus. This stimulates the posterior pituitary gland to 
release OT into the bloodstream. OT causes contraction of the myoepithelial cells surrounding 
the alveoli, forcing milk into the ducts. In humans, it takes 30 s to 1 min from stimulation to 
milk ejection. This process continues to function until weaning (Geddes, 2007; Gimpl & 
Fahrenholz, 2001). 
Experiments with OT-deficient mice, showed no obvious deficits in fertility, gestation, or 
parturition. The maternal behaviour both pre- and postpartum was normal as the females built 
a typical nest and the offspring was cleaned and present in the nest after delivery. Even 
though the maternal behaviour seemed normal, the offspring of the OT-deficient females died 
within 24 hours after delivery. Histological analysis of the breast tissue confirmed that there 
were no deficits in milk production. Postpartum injections of OT given to the OT-deficient 
females produced enough milk ejection to keep the offspring alive as long as the injections 
continued. This showed that OT is required for milk ejection (Nishimori et al., 1996). 
OT was the first peptide hormone to have its structure determined, and in 1953 the sequence 
was published. OT is a cyclic peptide consisting of nine amino acid peptide with a disulfide 
bond creating a ring structure. The hormone is shown to be a member of an old group of nine 
amino acid peptides of similar structure, with ancestral forms found in various vertebrates and 
even invertebrates, but OT is almost exclusively mammalian. Since it is involved in two 
particularly mammalian aspects of reproduction; uterine contraction during labour and milk 
ejection during nursing, this may not be a coincidence (Insel et al., 1997; Gimpl & 
Fahrenholz, 2001). 
Like most neuropeptides, OT can exert both peripheral and central action. OT is synthesized 
in the hypothalamus, transported to the posterior pituitary and released to the blood stream in 
response to cervical dilation or suckling. The hormone also synthesizes in peripheral tissues 
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as the testis, ovary, uterus and placenta. Even breast carcinomas have been shown to produce 
OT. The main role for OT is in reproduction, as it regulates mating, pair bonding, pup care, 
nursing, learning, and memory. Research on OT-deficient mice has shown that OT may not 
be essential for all these functions, but the hormone is necessary for milk ejection (Insel et al., 
1997; Nishimori et al., 1996; Reversi et al., 2005). 
Purified myoepithelial cells can express OT mRNA and use it actively to synthesize OT. The 
local source of peptide within the normal breast demonstrates the existence of a local 
autocrine/paracrine loop. This could participate in the differentiation process of the mammary 
gland at different steps of evolution. Also, since OT stimulates endothelial cell growth, the 
OT production in the mammary lobules may be involved in the vascular remodelling of the 
tissue (Reversi et al., 2005). 
In the human genome only one OTR gene has been found, and it is believed that all of the 
central and peripheral actions caused by OT are due to activation of this receptor subtype. In 
the mammary gland the mRNA of OTR has been found in the myoepithelial cells surrounding 
the alveoli and ducts (Reversi et al., 2005). 
In a study of mammary gland and uterine OTR gene expression during gestation, parturition, 
and lactation, it has been confirmed that OTR mRNA levels are differently regulated in the 
two tissues. Uterine OTRs are up-regulated before parturition and then down-regulated, 
whereas myoepithelial OTRs gradually increase during gestation and remain up-regulated 
during the lactation (Breton et al., 2001; Reversi et al., 2005). 
The OTR contains seven transmembrane helices, which are highly conserved among the G 
protein-coupled receptor (GPCR) family (Gimpl et al., 2001). The OTR binds to different G-
proteins dependent on the cell conditions. This phenomenon is called receptor-G protein 
promiscuity. This enables OT to activate multiple responses at the same time in the same cell 
(Strunecká et al., 2009). 
G protein-coupled receptors (GPCRs) make up a great family of cell surface receptors with 
over 800 members. They are characterized by the presence of seven transmembrane α-helical 
segments separated by alternating intracellular and extracellular loop regions (Figure 1) 
(Jalink & Moolenaar, 2010; Rosenbaum et al., 2009). Two requirements have to be fulfilled 
for a protein to be classified as a GPCR, the first one being seven sequence stretches of 25 to 
35 succesive residues, believed to represent the seven α-helices, and the second requirement is 
the receptor’s ability to interact with a G-protein. The functional couplings of the GPCRs are 
gr eatly diverse as they have a number of alternative signalling pathways, interacting directly 
with a number of other proteins (Fredriksson et al., 2003). 
The receptor family can be divided into five subfamilies on the basis of their structure and 
sequence similarity; rhodopsin (family A), secretin (family B), glutamate (family C), adhesion 
and Frizzled/Taste2 (Fredriksson et al., 2003; Rosenbaum et al., 2002). Although they have 
these similarities, individual GPCRs have unique combinations of signal-transduction 
activities involving multiple G-protein subtypes, as well as G-protein-independent signalling 
pathways and complex regulatory processes (Rosenbaum et al., 2002). 
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The ligands for the GPCRs are very diverse: peptides, ions, lipids, nucleotids, proteins, ions, 
organic odorants, and even photons are able to mediate their message through these proteins 
(Fredriksson et al., 2003). Because of this, the GPCRs are among the essential nodes of 
communication between the internal and external environments of cells. GPCRs connect the 
binding of agonists to the activation of specific heterotrimeric GTP-binding proteins (G-
proteins), which leads to the modulation of downstream effector proteins (Rosenbaum et al., 
2002). GCPRs regulate the activity of a separate plasma-membrane-bound target protein, 
which can be either an enzyme or an ion channel, indirectly. A G protein, is mediating the 
interaction between the receptor and this target protein. If the target protein is an enzyme its 
activation can change the concentration of one or more intracellular mediators, and if the 
target protein is an ion channel, it can change the ion permeability of the plasma membrane. 
The intracellular mediators affected act in turn to alter the behaviour of yet other signalling 
proteins in the cell (Alberts et al., 2002). 
When stimulated by a ligand, GPCRs activate their respective G-protein-effector pathways 
instantly while they are recruited to specialized domains at the plasma membrane. Most 
GPCRs are desensitized after ligand stimulation (Jalink & Moolenaar, 2010). The process of 
desensitization involves multiple pathways, including phosphorylation of the receptor’s 
cytoplasmic tail, arrestin-mediated internalization into endosomes, receptor recycling and 
lysosomal degradation (Pierce et al., 2010). 
The receptors undergo conformational changes that enable them to activate trimeric G-
proteins when extracellular signalling molecules bind to them (Alberts et al., 2002). Model 
GPCRs have shown that switching from inactive to active conformation is associated with a 
change in the relative orientation of transmembrane domains 3 and 6, which then unmasks G-
protein binding sites (Gimpl et al., 2001). The G-proteins are attached to the cytoplasmic face 
of the plasma membrane, functionally coupling the receptors to enzymes or ion channels in 
this membrane. There are various types of G-proteins, each specific for a particular set of 
serpentine receptors and for a particular set of downstream target proteins in the plasma 
membrane. All have similar structure, however, and they operate in a similar way (Alberts et 
al., 2002).  
The G-protein consists of three subunits (α, β and γ). Each of these subunits is a member of a 
gene family. The G-proteins are often referred to by their α-subunits. Like so, the Gs 
heterotrimeric complex contains Gαs, Gq contains Gαq and so on. Four distinct α-subunit 
subfamilies are known: Gs-proteins interacts with adenylyl cyclase and stimulates the 
production of cyclic adenosine monophosphate (cAMP); Gi-proteins couple to inhibition of 
adenylyl cyclase and thereby production of cAMP, and also to activation of G-protein-
coupled inwardly rectifying potassium (GIRK) channels; Gq-proteins couple to the activation 
of phospholipase Cβ; and G12-protein couple to the activation of Rho guanine-nucleotide 
exchange factors (GEFs) (Pierce et al., 2010; Strunecká et al., 2009).The α-subunit is 
responsible for GTP and GDP binding and for GTP hydrolysis. When unstimulated the α-
subunit has GDP bound and the G-protein is inactive. The α-subunit releases the bound GDP, 
which allows GTP to bind in its place, when stimulated by an active receptor. With this 
exchange, the heterotrimer dissociates into two activated components; an α-subunit and a βγ-
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complex. The conformational change caused by GTP binding affects the surface of the α-
subunit associated with the βγ-complex in the heterotrimer in two ways. It causes the release 
of the βγ-complex, and makes the α-subunit adopt a new shape that allows interaction with its 
target proteins. The βγ-complex does not undergo any conformational changes, but its surface 
is now available to interact with a second set of target proteins (Alberts et al., 2002). 
The superfamily of GPCRs is one of the largest families of proteins in the mammalian 
genome. The OTR belongs to the rhodopsin family, which is the largest and most diverse 
family within the superfamily. Four groups have been found in the rhodopsin family; OT 
belongs to the β-group. This group includes 36 receptors; all known ligands to these receptors 
are peptides. The closest neighbours to the OTR in the phylogeny relationship are the three 
arginine vasopressin receptors (Fredriksson et al., 2003). In this family all except the V2 
receptor are coupled mainly to Gq/11 and activate phospholipase C (PLC) in response to 
agonist binding (Zingg & Laporte, 2003). OT can bind to two of the vasopressin receptors, 
V1a and V1b, although with low affinity. In particular tissues or under certain circumstances 
the actions of OT can be mediated by these vasopressin receptors (Reversi et al., 2005). The 
OTR also couples to Gs and Gi. Several intracellular signalling pathways are activated via Gq 
(Viero et al., 2010). 
Only one OTR type exists, and can be found in as various places as the pituitary, kidney, 
testes, ovary and mammary glands (Zingg, H., 1996). The regulation of OTR expression is 
tissue-specific and the OTR expression can be up- or downregulated, unlike many other 
GPCRs. Examples are the uterus where the expression of OTR is upregulated during gestation 
which leads to a strong increase in uterus sensitivity towards OT. After parturition, the 
expression of OTR decreases rapidly in the uterine whereas OTR expression in the mammary 
gland remains raised throughout the lactation period. Since the OTR expression is tissue-
specific regulated it enables circulating OT to switch its target organs and induce uterine 
contraction during parturition and milk 
ejection during lactation (Zingg & 
Laporte, 2003).  
The cyclic part of the OT molecule is 
lodged in the upper one-third of the 
receptor-binding pocket and interacts 
with transmembrane domains 3, 4 and 6 
when OT binds to the OTR (Figure 1 
1
). 
The linear C-terminal part of the OT 
molecule remains closer to the surface 
and interacts with the N-terminal 
domain and the first extracellular loop 
of the OTR (Zingg & Laporte, 2003; 
Postina et al., 1996).  
                                                 
1
 Figure 1: Reprinted from Trends in Endocrinology and Metabolism 14 (5), Zingg, H. & Laporte, S., The 
oxytocin receptor, 222-227, Copyright (2003), with permission from Elsevier. 
Figure 1. Schematic model of the structure of the 
oxytocin receptor and its interaction with the ligand 
(Zingg & Laporte, 2003)
1
.
 
8 
Evidence is provided for a specific contact site between an OT antagonist and residues 114-
116 located at transmembrane domain 3, close to the extracellular surface (Breton et al., 
2001).
 
 
Oxytocin receptor signalling 
OTR is able to couple to different G-proteins which give stimulation of various signalling 
cascades (Figure 3). Depending on the G-protein, OTR can give rise to opposite effects on the 
same cellular function (Strunecká et al., 2009). 
 
Figure 2. Schematic diagram of oxytocin receptor (OTR)-linked signalling pathways (Viero et al., 
2010)
2
.  
OTR located on smooth muscle cells, such as uterine myometrial cells or mammary gland 
myoepithelial cells, induces contraction upon activation, which is triggered by an increase in 
intracellular Ca
2+
. A Gαq/11-mediated stimulation of PLC activity is involved in the increase in 
intracellular Ca
2+
 (Zingg & Laporte, 2003). Contractions induced by OT are also mediated via 
the activation of the Rho kinase pathway. The proliferative effects of OT appear to be Gq-
linked and are probably involving mitogen-activated protein kinase (MAPK) activation, 
leading to c-fos and c-jun induction (Viero et al., 2010). Anti-proliferative effects (# in Figure 
2
2
) observed in certain cell types have been reported to be Gi-mediated, dependent on 
                                                 
2
 Figure 2: Reprinted from CNS Neuroscience & Therapeutics 16, Viero, C., Shibuya, I., Kitamura, N., 
Verkhratsky, A., Fujihara, H., Katoh, A., Ueta, Y., Zingg, H., Chvatal, A., Sykova, E. & Dayanithi, G, Oxytocin: 
Crossing the Bridge between Basic Science and Pharmacotherapy, 138-156, Copyright  (2010), with permission 
from Elsevier. 
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epidermal growth factor receptors (EGFR) transactivation and MAPK activation via a 
PLC/PI3K/ cellular sarcoma tyrosine kinase (c-Src)-dependent pathway that ultimately leads 
to a sustained activation of the cell cycle inhibitor (Rimoldi et al, 2003). 
The OT-mediated proliferative, trophic, contractile, and antiproliferative effects are supported 
by complex networks of signalling pathways. Which OT responses that occur in any given 
cell depends on the specific cell type as well as on the specific plasma membrane domains in 
which the receptor is located (Viero et al., 2010). OT may stimulate, inhibit or have no effect 
on cell proliferation, depending on the cell system (Guzzi et al., 2002). 
GPCRs are rapidly internalized and disappear from the cell surface after activation. This 
phenomenon also applies to the OTR. The OTR gathers with β-arrestin into defined 
punctuated regions of the plasma membrane, which suggests that OTRs are targeted into 
clathrin-coated pits for internalization. Internalization of the receptor and β–arrestin into large 
endocytic vesicles is induced by prolonged stimulation of the OTR (Zingg & Laporte, 2003). 
Localization of human OTR in caveolin-1 enriched microdomains radically alters its 
regulatory effects on cell growth. A study has shown that OT inhibits cell proliferation when 
most of the OTRs are excluded from caveolin-enriched domains, but when OTRs are targeted 
to caveolin-enriched domains after being fused to caveolin-2, OT has a strong mitogenic 
effect. This suggests that the location of the receptor in the cell membrane may favour 
coupling to different G protein-mediated signalling pathways. Also the fraction of OTRs 
residing in caveolae domains may influence the proliferative or anti-proliferative effects of 
OT (Gimpl et al., 2008; Guzzi et al., 2002). 
Since OTRs have the ability to couple to several G-proteins that exhibits opposite effects, the 
definition of “agonist” and “antagonist” is difficult to make. All OTR ligands presumably 
have the potential to stimulate dual signalling responses. Therefore, an “agonist” or 
“antagonist” should be defined based on e.g. cell type, stage of development, or 
phosphorylation level (Viero et al., 2010). 
A study of human lactating and non-lactating mammary glands showed that OTR 
immunoreactivity was localized in the ductal and/or glandular epithelium rather than the 
myoepithelial as was previously thought. Both lactating and non-lactating tissue showed the 
same staining pattern (Kimura et al., 1998). Another study showed that the major OTR 
immunoreactivity was localized in the outer, myoepithelial cell layer (Bussolati et al., 1996). 
 A recent study shows that OTR localizes to several compartments within nuclei of cells 
derived from neoplastic breast epithelium (MCF7). An OTR-GFP plasmid, with green 
fluorescence protein (GFP) at the carboxyl terminus, was created, and the functionality was 
confirmed by cytological relocalization of the GFP following OT-treatment of cells. In the 
MCF7 cells OTR-GFP was translocated from cell membrane / cytoplasm to the nuclei after 
treatment with exogenous OT (10
-7
M). Both internalization and nuclear localization of the 
OTR is strictly dependent on OT treatment of the cells, according to immunoflourescence 
studies in MCF7 cells. Only a few of the cytoplasmic OTRs entered the nucleus, but once 
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transported into the nucleus the OTR remained there regardless of the extracellular presence 
of OT for at least several hours (Kinsey et al., 2007). 
Oxytocin effects on cell proliferation and cancer 
Nowadays it is known that women who have breast fed their babies run a lower risk of 
developing breast cancer, but the protective factors are not clearly identified. One early 
hypothesis states that breast cancer is caused by the action of superoxide free radicals released 
when acinar gland distension causes ischemia in the small blood vessels. The acinar gland 
distension would be relieved by OT production from nipple stimulation, causing contraction 
of the myoepithelial cells, aiding the active elimination of carcinogenic fluid from the breast 
(Murrell, T., 1995). More recently findings however, support the possibility of OT being a 
modulator of breast cancer progression since it may directly affect cell differentiation 
(Reversi et al., 2005). 
An early study on human breast cancer cell lines (MCF7, T47D and MDA-MB231) shows 
that OT plays a role in control of cell growth. The cells were treated with OT three times in 
three different doses (10
-9
M, 10
-8
M, and 10
-7
M). 10
-8
M and 10
-7
M OT clearly reduced the cell 
proliferation rate in these three cell lines. The cells also showed a change in 
immunophenotype, possibly suggesting differentiation. OT has earlier been shown to induce 
cell differentiation in developing mouse mammary gland. This suggests that malignant cells 
can be compared to the small minority of undifferentiated stem cells which are detected 
within the population of the normal mammary gland (Cassoni et al., 1994). An in vivo 
experiment shows that the results above are reproducible in living rodents. OT significantly 
reduced proliferation in implanted breast carcinomas (Cassoni et al., 1996). Yet another study 
shows that cAMP increases significantly in OT treated breast carcinoma cells (MDA-MB231) 
while the inositol-Ca
2+
 pathway is not activated. Also, the anti-proliferative effect was 
inhibited by treatment of PKI (6-22) amide, a PKA inhibitor. Taken together, this indicates 
that the anti-proliferative effect of OT is strictly related to the cAMP-PKA pathway, in breast 
epithelial cells that lack contractile activity (Cassoni et al., 1997). 
In a study ten breast carcinoma cell lines were examined regarding the presence of OTR and 
OT mRNA. All the cell lines expressed OTR mRNA, but only five of ten of the cell lines 
expressed OT mRNA. A local OT synthesis was found in both normal myoepithelial cells and 
different breast carcinoma cell lines; they were able to synthesize and secrete different 
amounts of OT. Normal epithelial cells isolated from human breast were found to contain 
mRNA for OT, but they did not actively produce and release OT in the culture medium. This 
suggests that an unexpected autocrine loop involving myoepithelial cells may exist. OT have 
been proved to induce myoepithelial cell proliferation and differentiation, which means that 
the presence of an OT synthesis within the breast could represent a local peptide source 
directly available for myoepithelial cell differentiating processes (Cassoni et al., 2006a). 
Tumour-derived endothelial cells obtained from breast carcinomas (B-TEC) have been used 
to verify some of the differences between “normal” and tumour-related endothelium. Tumour-
derived endothelial cells differ from normal endothelial cells because of some morphologic, 
functional, and structural changes. B-TEC showed the characteristics to grow and to organize 
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in capillary like structures. In a study, mRNA for OTR, but not for OT was found in B-TEC, 
and about 80% of the cells were positive for OTR in the cell membrane. Also the cell 
proliferation was significantly increased after addition of OT, and the effect was dose 
dependent as a higher concentration of OT increased cell proliferation more. As of this result 
it is clear that the stimulating effects of OT on cell growth and migration are not limited to 
“normal” endothelial cells, but also effects endothelial cells derived form neoplastic tissue, 
specifically B-TEC. This gives OT a possible role in angiogenetic processes under non-
neoplastic (i.e., wounding processes) and neoplastic conditions (Cassoni et al., 2006b). Since 
studies have shown that OT is synthesized and locally released by breast carcinoma cells, a 
local source of OT within breast cancers could be effective in regulating the neoformed 
vessels even at low concentrations that previously resulted biologically ineffective on the 
neoplastic epithelial cells themselves (Cassoni et al., 1994; Cassoni et al., 1996; Cassoni et 
al., 2006a). 
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MATERIALS AND METHODS 
Cell line 
The canine mammary carcinoma cell line CMT-U27 was used in this study (Hellmén, E., 
1992). The cell line was routinely cultured in modified RPMI-1640 (without L-glutamine and 
phenol red) (Sigma-Aldrich, St Louis, MO, USA) supplemented with 200mM L-glutamine 
(National Veterinary Institute, [SVA], Uppsala, Sweden), 10% foetal bovine serum (Sigma-
Aldrich) and antibiotics (6 mg/ml penicillin and 5 mg/ml streptomycin [SVA]). Cells were 
grown in 25 cm
2
 Falcon flasks in a humidified atmosphere of 5% CO2 and 95% air at 37°C. 
Cell passages used and time-table for the cell culturing is shown in Table 1. 
Table 1. List of passage number of the cells, number of days between the assays and reseeding cells 
and changing cell culture medium 
Assay 
number 
Cell passage 
number 
No. of days from 
reseeding to assay 
No. of days from change of 
cell culture medium to assay 
Oxytocin1 145 8 1 
Oxytocin2 146 7 2 
Oxytocin3 146 6 3 
Oxytocin4 149 5 5 
Oxytocin5 149 5 5 
Oxytocin6 150 7 7 
 
Cell proliferation 
The kit used to evaluate the cell proliferation was Colorimetric Cell Viability Kit I (CCVK-I) 
(PromoKine, Heidelberg, DE). CCVK-I-solution in the kit contains the tetrazolium salt WST-
8 that are reduced to water-soluble, orange formazan dyes by dehydrogenases present in 
viable cells. The absorbance of the formazan dye is proportional to the number of 
metabolically active cells and can be measured directly from a 96-well plate without 
additional processing. 
To decide which cell concentrations that should be used to get a good standard curve a cell 
proliferation assay was performed three times before the addition of OT was done. In the first 
test the concentrations was ranging from 3 750 to 60 000 cells/ml, and in the two following 
tests the concentrations were ranging from 15 000 to 90 000 cells/ml. Cells were seeded in 
triplicates in 96-well plates. After incubation at 37°C for 22 hours CCVK-I was added and the 
plate was incubated for another two hours. The absorbance was read in a microplate reader 
(Infinite M1000; Tecan Group Ltd., Männedorf, CH) at 405 nm after totally 24 and 48 hours 
incubation. 
To decide if the cell proliferation in the CMT-U27 cells was affected upon stimulation with 
the OT, three series of cells were seeded in triplicates in six concentrations, ranging from 
15 000 to 90 000 cells/ml, in 96-well plates. 10
-6
M and 10
-7
M OT (Partoxin 10 IU/ml; 
Pharmaxim AB, Helsingborg, SE) was added after incubation at 37°C for 22 hours. CCVK-I-
solution (PromoKine) was added after 20 minutes incubation with OT. The absorbance was 
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read in a microplate reader (Infinite M1000) at 405 nm after totally 24 and 48 hours 
incubation. The cell proliferation assay was repeated six times. 
Three series were prepared for each plate (Figure 3); one standard series without addition of 
OT, one series with addition of 10
-6
M OT and one series with addition of 10
-7
M OT (Bogacki 
et al., 2002; Cassoni et al., 1996). For each series a set of blanks was also prepared.  
Figure 3. The plate was prepared in this manner, with all samples in triplicates.  
ST: Standard samples, SM1: Samples with addition of 10
-6
M oxytocin (OT), SM2: Samples with 
addition of 10
-7
M OT. 
The results from the microplate reader were run through MultiCalc and then statistical 
analysis on growth curves was carried out with GraphPad Prism software version 5.02 for 
Windows, using one-way analysis of variance (ANOVA, Bonferroni's Multiple Comparison 
Test). 
Immunocytochemistry 
The OTR antibody used ([A-16]: sc-34078) was a goat polyclonal anti-human antibody from 
Santa Cruz Biotechnologies Inc. (Santa Cruz, CA, USA). It has been proved to detect OTR of 
human, rat and mouse origin and to determine if the antibody could detect OTR of canine 
origin, resting canine mammary gland was used. 
Sections of resting and lactating canine mammary gland tissue were used as positive controls. 
Five µm sections of the lactating mammary gland were cut in a cryostat at -25°C, and either 
stained immediately or stored at -70°C until used, in the project. 
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The cells were grown on cover slips for the immunocytochemistry. The cover slips were 
rinsed in 70% alcohol, PBS and cell culture medium (RPMI-1640; Sigma-Aldrich). The cover 
slips were then placed in 2.5 ml Petri dishes. The cells were diluted to appropriate 
concentrations (about 80% confluence is desired) and 2.5 ml cell suspension was added to 
each Petri dish, and incubated at 37°C overnight. 
The sections and cells were fixated in methanol, and then blocked in avidin and biotin (Vector 
Laboratories Inc., Burlingame, CA, USA) for 15 minutes each. Normal horse serum (diluted 
1:50 in 0.05 M Tris-HCl pH 7.6 (Tris-buffer)) was followed by overnight incubation of the 
OTR antibody (diluted in Tris-buffer) at 4°C. Negative controls were incubated with only 
Tris-buffer. Biotinylated anti-goat IgG (diluted 1:200 in Tris-buffer) was subsequently 
incubated for 30 min and then the ABC-Elite system (Vector Laboratories) was used. Nova 
RED or 3,3’-diaminobenzidine (Vector Laboratories) was used as chromogen for both tissue 
and cells. After rinsing in distilled water, the slides were counterstained with Mayer´s 
haematoxylin. Finally, the slides were rinsed in tap water, dehydrated and the cover slips were 
mounted onto slides, while the slides were covered with cover slips. The 
immunocytochemistry was repeated three times. 
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RESULTS 
Cell proliferation standard curve 
In each well 100 µl of the cell suspension was added, which means 375 to 6 000 cells/well for 
the first test. In the lowest two concentrations there were too few cells for the microplate 
reader to detect properly. In the two following tests the concentrations were ranging from 
15 000 to 90 000 cells/ml, which means 1 500 to 9 000 cells/well, which gave two nice curves 
(Figure 4). The recommendations for the kit was that 1 000 to 25 000 adhesive cells/ml 
should be used in the assay. 
Effect of oxytocin addition on cell proliferation 
The aim of the cell proliferation assays was to determine if addition of OT has any effect on 
the cell growth. Indeed, there was a significant inhibition of the cell proliferation in four cell 
concentrations in three of the assays (Figure 5). In five of the six assays there seems to be 
inhibition in cell growth, although not significant (Figure 6). In two assays both OT 
concentrations inhibited the cell proliferation and only 10
-6
M OT acted inhibiting in the last 
assay performed. 
  
Figure 4. Assay for standard curve was performed three times to 
determine the most suitable cell concentrations to use in the cell 
proliferation assay. 
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Figure 5. Diagrams of the significant inhibition of cell growth in three assays. Bars with different 
superscripts within each diagram are different (P < 0.05). In Oxytocin 1 significant inhibition of cell 
proliferation was achieved at the cell concentration of 45 000 cells/ml. In Oxytocin 3 significant 
inhibition of cell proliferation was achieved at the cell concentrations 60 000 cells/ml and 75 000 
cells/ml. In Oxytocin 6 significant inhibition of cell proliferation was achieved at the cell 
concentration 75 000 cells/ml. 
Note: The unit for cell concentration is cells/ml and the result was calculated as cells/well from the 
plate. Each well contained 100 ul cell suspension, therefore the cell concentration is ten times higher 
than the number of cells in the results. 
 
In the first, third, and sixth assay a significant decrease in cell proliferation was observed, 
compared with the control samples (Figure 6). Both 10
-6
M and 10
-7
M oxytocin was 
significantly inhibiting the cell proliferation in the first and third assay. In the sixth assay only 
10
-6
M oxytocin was significantly inhibiting the cell proliferation. 
The significant decrease in cell proliferation observed was; in the first assay at 45 000 
cells/ml with 10
-6
M OT (*, P < 0,05) and 10
-7
M OT (**, P < 0,01). In the third assay at 60 000 
cells/ml with 10
-6
M OT (**, P < 0,01) and 10
-7
M OT (*, P < 0,05) and 75 000 cells/ml with 
10
-6
M OT (***, P < 0,001) and 10
-7
M OT (***, P < 0,001). In the third assay at 75 000 
cells/ml there was also a significant difference in cell proliferation between 10
-6
M and 10
-7
M 
OT (*, P < 0,05). In the sixth assay at 75 000 cells/ml with 10
-6
M OT (**, P < 0,01). 
17 
Figure 6. Cell proliferation curves, where absorbance are relative to proliferating cells. 
 
Immunocytochemistry 
Immunocytochemistry analysis on cells was repeated three times, with cell passage no. 149 
twice and 150 once. The first analysis showed no staining in cells or controls, probably due to 
a technical problem. The two following analyses showed staining in the cell membrane and 
cytoplasm in some cells, in the cytoplasm, nuclear membrane and in the nucleus in some 
cells, and no staining at all in some cells (Figure 7). 
Resting mammary gland was used as control in the first two analyses, and in the third analysis 
lactating mammary gland was used as control. Staining of the resting mammary gland shows 
that the receptors are located in the cell membrane, whereas they are located in the cytoplasm 
and nucleus in the lactating mammary gland (Figure 7). 
The oxytocin receptor antibody was tested in four concentrations; 1:50, 1:100, 1:250 and 
1:1000, where 1:200 proved to give best staining. 
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Figure 7. Immunocytochemistry of the cell line CMT-U27 and the controls – lactating and resting 
mammary gland demonstrating expression of the oxytocin receptor( 40x objective). The cells (A) show 
different patterns of staining; some (1) show staining in the cytoplasm of the cell and the nucleus is 
unstained. Some (2) show marked staining in the nuclear membrane and the nucleus. Some elongated 
cells seem to be unstained. Lactating mammary gland (B) shows staining in the nuclei in many cells 
surrounding the alveoli (3) and some cells are weakly stained. Resting mammary gland (C) shows 
staining in the cell membrane (4) and the cytoplasm (5) of some cells surrounding intralobular ducts. 
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DISCUSSION 
The aim of this project was to find out if the cell proliferation in CMT-U27 cells was affected 
upon stimulation with the OT, and given the results it is clear that OT has an inhibiting effect 
on this cell line. The presence of oxytocin receptors was also investigated and staining of the 
oxytocin receptor showed staining in the cell membrane, cytoplasm and also in the nuclear 
membrane and in the nuclei of the cells. Since there was staining in the nuclear membrane 
and in the nuclei, the OTRs have been activated (Kinsey et al., 2007). 
The cell proliferation assay was repeated six times and the proliferation curves show both 
similarities and differences. Two and four curves show similar cell numbers and growth rates, 
while the two groups compared to each other show different cell numbers and growth rates 
(Figure 7). This can be due to when the cell culture medium was changed in relation to the 
assay, when the cells last were reseeded before the assay (Table 1), or in which stadium of the 
cell cycle the cells are. It is difficult to say which stadium of the cell cycle the cells were since 
that was not a part of this project, but it is probable that a larger portion of the cells were due 
to divide in the first and third assay. Cell culture medium was changed at almost the same 
intervals, one to three days before the first three assays and five to seven days before the last 
three. This does not seem to correlate with the cell proliferation. The cells were reseeded at 
five to eight days before the assays, and the only correlation between differences in cell 
proliferation and the reseeding is that the first and third assay was done after an even number 
of days, six and eight, after the reseeding. The cell line has been shown to have a growth rate 
of 48h, (Hellmén, E., 1992). All cells do not divide at the same time, so it is possible that 
more cells in a dividing state have been collected in the first and third assay. 
The statistical analysis in GraphPad Prism was performed when all assays were done and that 
revealed that the oxytocin had had more inhibiting effect than indicated in the curves (Figure 
6). When the third assay was done it seemed that there had been no inhibition at all in the cell 
growth, so when performing the fourth and fifth assay two different flasks of OT was used, in 
order to investigate if the first flask had expired. No significant inhibition was achieved in 
either the fourth or the fifth assay. In fact it seems as if the cell proliferation was low over all. 
In the sixth assay, where the second flask of OT also was used, inhibition in cell growth was 
achieved. 
The cell culture medium was changed to RPMI-1640 without phenol red (Sigma-Aldrich) 
before the cell proliferation assays were performed, because phenol red can have the same 
effect as oestrogen and stimulate proliferation within oestrogen-positive cells (Berthois et al., 
1986). The cell line CMT-U27 can grow in serum-free medium (Hellmén, E., 1992) and 
maybe that would have given different results when adding the oxytocin, but that was not 
done in this project. It could also have given a better understanding of what activated the 
oxytocin receptors. The cells have been tested for oxytocin synthesis (personal 
communication, E. Hellmén), but if the amount of oxytocin they produce is enough to activate 
the receptors is not clear. It is possible that some ingredients in the cell medium stimulate the 
activation of the oxytocin receptors. That might be of interest to find out in further studies of 
this cell line. Another study has shown that myoepithelial cells from normal breast tissue 
synthesize and release OT in cell medium. Also some breast carcinoma cell lines can 
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synthesize OT (Cassoni et al., 2006a). An earlier study has shown that OT stimulates 
differentiation in myoepithelial cells within organotypic cultures of mouse mammary gland 
and in vivo in non-lactating mouse mammary gland. This means that an OT synthesis within 
the mammary gland could represent a local peptide source directly available for myoepithelial 
cell differentiation (Sapino et al., 1993). 
As previously shown growth in breast cancer cell lines is inhibited with the addition of OT.  
The canine mammary tumour cell line used in this project shows similar characteristics. In 
some cases a significant inhibition was reached. Both 10
-6
M and 10
-7
M OT have an inhibiting 
effect on the cell proliferation. In a previous study on breast cancer cell lines as low doses of 
OT as 10
-9
M have been shown to have an inhibiting effect (Cassoni et al., 1994). 
Further studies of the cell line CMT-U27 could include another measure of the amounts of 
OT synthesized. If the doses are high enough to affect the cell proliferation it would be 
interesting to examine how it is affecting the cells. It would also be interesting to find out 
which of the cells that synthesize OT, and if it is those with OTRs a possible autocrine loop 
could be investigated. 
The immunocytochemistry showed some interesting results regarding the location of the 
OTRs in the cells. No OT was added to the cells prior to the staining, but the cells showed 
staining in the cell membrane, cytoplasm and nucleus nevertheless. There were three groups 
of cells of which some showed staining in the cell membrane and cytoplasm, some showed 
staining in the nuclei and nuclear membrane, and some showed no staining at all. This cell 
line has been shown to produce OT itself (personal communication, E. Hellmén), and with 
that in mind the behaviour of the receptors may not be that strange. If the amount of OT is 
enough for the cells to stimulate themselves, it can induce translocation of the OTRs from the 
cell membrane and cytoplasm to the nuclear membrane or the nuclei (Kinsey et al., 2007).  
Further studies of the receptor location in the cell membrane could give an indication of 
which signalling pathways are used in the cells studied. It has been proposed that OT inhibits 
cell proliferation when OTRs in mouse mammary carcinomas are not targeted to lipid rafts 
enriched in caveolin-1 (Cassoni et al., 1996). Also it has been observed that the cAMP-PKA 
pathway was involved in the antiproliferative effect in breast, endometrial, bone and nervous 
tumours. It seems that the intracellular cAMP levels are dose-dependent to the levels of OT 
added. The highest anti-proliferative effect was reached when adding 10
-7
M OT, and so was 
the highest concentration of cAMP (Amico et al., 2002; Cassoni et al., 1997; Cassoni et al., 
1998). 
Two interesting things were also noted in the control sections in the immunocytochemistry 
analysis. Resting and lactating mammary gland tissue were used as controls, but not 
simultaneously. When studying the slides microscopically, it was clear that the OTRs were 
located in different parts of the cell in the different tissues. Receptors are located in the cell 
membrane and cytoplasm in the resting mammary gland, but in lactating mammary gland 
receptors are also visible in the nuclear membrane and in the nucleus of the cell. This has 
been reported for a breast cancer cell line, where OT treatment induced translocation of the 
OTR from the cell membrane and cytoplasm to the nuclei (Kinsey et al., 2007). Resting 
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mammary gland should not be a target tissue for OT, whereas the lactating mammary gland 
should be. This can explain the difference in the location of the receptors. 
The function of OTR within mammary carcinomas is not yet understood. It is thought that the 
effects of OT are mediated via the OTRs, since OT has been reported to inhibit the growth of 
human breast cancer cells and mouse mammary carcinoma cells (both in vitro and in vivo), 
and to decrease the rate of tumour formation. The location of the OTR in the cell membrane, 
changes in the amount or binding of the OTRs may regulate mammary differentiation or 
neoplasia, since OT has been reported to inhibit growth and promote differentiation in human 
breast cancer cells (Amico et al., 2002; Cassoni et al., 1994; Cassoni et al., 1996; Cassoni et 
al., 2002). 
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CONCLUSION 
OT proved to inhibit the cell proliferation in the studied CMT-U27 cell line. The 
immunocytochemical analyses also revealed that some of the cells have OTRs. The 
localization of the receptors indicates that the cells synthesize OT themselves since the 
receptors had been internalized although no OT was added prior to the immunocytochemistry 
analyses. Further analyses need to be conducted to determine which of the cells that produce 
the OT. 
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